
Tubulis Doses First Patient in Phase I/IIa Trial of ADC TUB-030 for Advanced Solid Tumors
Tubulis Advances ADC TUB-030 into Clinical Trials for Advanced Solid Tumors Tubulis, a biopharmaceutical company focused on antibody-drug conjugates (ADCs), announced a significant milestone today with the dosing of the first patient in its Phase I/IIa clinical trial, 5-STAR 1-01…












